Luye Pharma, a China R&D-based company, has completed three China Phase I trials of a novel anti-depressant (LY03005), a serotonin-norepinephrine-dopamine triple reuptake inhibitor. The molecule, ansofaxine hydrochloride extended release tablets, passed all three tests. Luye, which holds IP for the drug, is concurrently developing LY03005 for China and the US markets, with a Phase I trial underway in the US.
Help employers find you! Check out all the jobs and post your resume.
